210 related articles for article (PubMed ID: 14567887)
1. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment.
Roulier R; Chabert-Orsini V; Sitri MC; Barry B; Terriou P
Reprod Biomed Online; 2003 Sep; 7(2):185-9. PubMed ID: 14567887
[TBL] [Abstract][Full Text] [Related]
2. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
4. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
European and Middle East Orgalutran Study Group
Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
[TBL] [Abstract][Full Text] [Related]
5. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
7. Gonadotrophin-releasing hormone antagonists for assisted conception.
Al-Inany H; Aboulghar M
Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
[TBL] [Abstract][Full Text] [Related]
8. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.
Nikolettos N; Al-Hasani S; Felberbaum R; Demirel LC; Riethmüller-Winzen H; Reissmann T; Schöpper B; Sturm R; Diedrich K
Eur J Obstet Gynecol Reprod Biol; 2000 Nov; 93(1):91-5. PubMed ID: 11000511
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences.
Olivennes F; Diedrich K; Frydman R; Felberbaum RE; Howles CM; ;
Reprod Biomed Online; 2003 Jun; 6(4):432-8. PubMed ID: 12831588
[TBL] [Abstract][Full Text] [Related]
12. Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.
Vlaisavljevic V; Reljic M; Lovrec VG; Kovacic B
Reprod Biomed Online; 2003 Oct; 7(3):301-8. PubMed ID: 14653888
[TBL] [Abstract][Full Text] [Related]
13. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
14. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction.
Sauer MV; Thornton MH; Schoolcraft W; Frishman GN
Reprod Biomed Online; 2004 Nov; 9(5):487-93. PubMed ID: 15588464
[TBL] [Abstract][Full Text] [Related]
16. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
17. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
18. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
19. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
20. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
